Prostate Irreversible Electroporation Study

Launched by CHINESE UNIVERSITY OF HONG KONG · Mar 13, 2025

Keywords

ClinConnect Summary

The Prostate Irreversible Electroporation Study is looking at a new treatment option for men with localized prostate cancer. Traditional treatments like surgery and radiation can lead to side effects, such as urinary problems and erectile dysfunction. This study focuses on a method called irreversible electroporation, which aims to target and destroy only the cancerous part of the prostate while sparing healthy tissue. The goal is to see how safe and effective this treatment is for managing prostate cancer.

To be eligible for the study, participants need to be men aged between 40 and 85 years who have been diagnosed with localized prostate cancer and have visible cancer spots on their MRI scans. Not everyone can join; for example, those with active infections or certain bladder issues won't be able to participate. If someone qualifies and chooses to join, they can expect careful monitoring and support throughout the study as researchers gather information to better understand this treatment approach. This research could help improve options for men facing prostate cancer in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Men aged between 40 - 85 years
• • Visible index lesion(s) on MRI
• • Found to have localized prostate cancer after MRI-USG fusion targeted biopsy or USG-guided template biopsy: Clinical tumour stage \<=T2, or Gleason score \<=7, or PSA \<= 20 ng/ml
• Exclusion Criteria:
• • Patients unfit for contrast MRI exam
• • Patients with active urinary tract infection
• • Patients with bladder pathology including bladder stone and bladder cancer
• • Patients with urethral stricture
• • Patients with neurogenic bladder and/or sphincter abnormalities
• • Patients who fail to give informed consent